253 related articles for article (PubMed ID: 22506633)
1. Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature.
Lindsley CW; Hopkins CR
Expert Opin Ther Pat; 2012 May; 22(5):461-81. PubMed ID: 22506633
[TBL] [Abstract][Full Text] [Related]
2. Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research.
Litim N; Morissette M; Di Paolo T
Neuropharmacology; 2017 Mar; 115():166-179. PubMed ID: 27055772
[TBL] [Abstract][Full Text] [Related]
3. Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's disease.
Amalric M; Lopez S; Goudet C; Fisone G; Battaglia G; Nicoletti F; Pin JP; Acher FC
Neuropharmacology; 2013 Mar; 66():53-64. PubMed ID: 22664304
[TBL] [Abstract][Full Text] [Related]
4. Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.
Niswender CM; Jones CK; Lin X; Bubser M; Thompson Gray A; Blobaum AL; Engers DW; Rodriguez AL; Loch MT; Daniels JS; Lindsley CW; Hopkins CR; Javitch JA; Conn PJ
ACS Chem Neurosci; 2016 Sep; 7(9):1201-11. PubMed ID: 27441572
[TBL] [Abstract][Full Text] [Related]
5. Recent progress in the development of mGluR4 positive allosteric modulators for the treatment of Parkinson's disease.
Lindsley CW; Niswender CM; Engers DW; Hopkins CR
Curr Top Med Chem; 2009; 9(10):949-63. PubMed ID: 19754407
[TBL] [Abstract][Full Text] [Related]
6. Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
Bennouar KE; Uberti MA; Melon C; Bacolod MD; Jimenez HN; Cajina M; Kerkerian-Le Goff L; Doller D; Gubellini P
Neuropharmacology; 2013 Mar; 66():158-69. PubMed ID: 22491024
[TBL] [Abstract][Full Text] [Related]
7. A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential.
Goudet C; Vilar B; Courtiol T; Deltheil T; Bessiron T; Brabet I; Oueslati N; Rigault D; Bertrand HO; McLean H; Daniel H; Amalric M; Acher F; Pin JP
FASEB J; 2012 Apr; 26(4):1682-93. PubMed ID: 22223752
[TBL] [Abstract][Full Text] [Related]
8. Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease.
Amalric M
Curr Opin Pharmacol; 2015 Feb; 20():29-34. PubMed ID: 25462289
[TBL] [Abstract][Full Text] [Related]
9. mGlu
Charvin D
Neuropharmacology; 2018 Jun; 135():308-315. PubMed ID: 29578036
[TBL] [Abstract][Full Text] [Related]
10. mGluR4 positive allosteric modulators with potential for the treatment of Parkinson's disease: WO09010455.
East SP; Gerlach K
Expert Opin Ther Pat; 2010 Mar; 20(3):441-5. PubMed ID: 20180624
[TBL] [Abstract][Full Text] [Related]
11. Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors.
Marino MJ; Conn PJ
Curr Opin Pharmacol; 2006 Feb; 6(1):98-102. PubMed ID: 16368268
[TBL] [Abstract][Full Text] [Related]
12. Neurobiological Insights from mGlu Receptor Allosteric Modulation.
O'Brien DE; Conn PJ
Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26647381
[TBL] [Abstract][Full Text] [Related]
13. Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia.
Kanuma K; Aoki T; Shimazaki Y
Recent Pat CNS Drug Discov; 2010 Jan; 5(1):23-34. PubMed ID: 19832691
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.
Célanire S; Campo B
Expert Opin Drug Discov; 2012 Mar; 7(3):261-80. PubMed ID: 22468956
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.
Duty S
Br J Pharmacol; 2010 Sep; 161(2):271-87. PubMed ID: 20735415
[TBL] [Abstract][Full Text] [Related]
16. Metabotropic glutamate receptor 5-positive allosteric modulators for the treatment of schizophrenia (2004-2012).
Lindsley CW; Stauffer SR
Pharm Pat Anal; 2013 Jan; 2(1):93-108. PubMed ID: 24236973
[TBL] [Abstract][Full Text] [Related]
17. Reprint of Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2.
Lundström L; Bissantz C; Beck J; Dellenbach M; Woltering TJ; Wichmann J; Gatti S
Neuropharmacology; 2017 Mar; 115():115-127. PubMed ID: 28216000
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of metabotropic glutamate receptor allosteric modulators: structural basis and therapeutic potential for CNS disorders.
Gregory KJ; Noetzel MJ; Niswender CM
Prog Mol Biol Transl Sci; 2013; 115():61-121. PubMed ID: 23415092
[TBL] [Abstract][Full Text] [Related]
19. Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.
Maksymetz J; Moran SP; Conn PJ
Mol Brain; 2017 Apr; 10(1):15. PubMed ID: 28446243
[TBL] [Abstract][Full Text] [Related]
20. Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).
Celanire S; Sebhat I; Wichmann J; Mayer S; Schann S; Gatti S
Expert Opin Ther Pat; 2015 Jan; 25(1):69-90. PubMed ID: 25435285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
